Suggest that FOXO1 expression is a favorable prognostic factor in non-small cell lung cancer.

Our findings suggest that Prx1 may modulate the chemosensitivity of lung cancer to docetaxel through suppression of FOXO1-induced apoptosis.

These findings suggest for the first time that FOXO1 is a promising candidate substrate for JNK, and the FOXO1-dependent DNA damage repair may be regulated positively by the JNK pathway in H1299 lung cancer cells.

Low FOXO1 expression is associated with non-small cell lung cancer.

FOXO1 plays dual roles in TKI resistance through posttranslational modifications in non-small cell lung cancer and this study provides a possible strategy for treatment of TKI-resistant non-small cell lung cancer patients.

we found that miR-155 promoted non-small cell lung carcinomas (NSCLC) cell proliferation through inhibition of FoxO1 and the subsequent increase of ROS generation. Our findings highlight miR-155/FoxO1/ROS axis as a novel therapeutic target for the inhibition of NSCLC growth.

our study revealed miR-411 promoted cell proliferation of lung cancer by targeting tumor suppressor gene FOXO1 and miR-411 might be a potential target for lung cancer therapy.

LAT1-NAD+-SIRT1 signaling is activated in tumor tissues of patients with non-small cell lung cancer; NAD+ synthesis regulates the SIRT1-FOXO1 apoptotic pathway in response to NQO1

UBE2T promotes radiation resistance in non-small cell lung cancer via inducing epithelial-mesenchymal transition and the ubiquitination-mediated FOXO1 degradation.